Objective This study aimed to analyze the incidence and mortality of cervical cancer in tumor registration areas of Yunnan province in 2020,as well as the trend of incidence and mortality from 2012 to 2020,in order to provide a basis for the prevention and treatment of cervical cancer in Yunnan province. Methods The data of cervical cancer incidence and mortality were collected and sorted out in tumor registration areas of Yunnan province from 2012 to 2020.The crude incidence,crude mortality,age-standardized incidence rate by World standard population(ASIRW)(referred to the World standard incidence),age-standardized mortality rate by World standard population(ASMRW)(referred to the World standard mortality)and other indicators of cervical cancer in 2020 were statistically analyzed according to the urban and rural areas.The annual percent change(APC)was used to evaluate the changing trend of cervical cancer incidence and mortality from 2012 to 2020,and the GM(1,1)model was used to predict the crude incidence and ASIRW from 2021 to 2025. Results In 2020,there were 2 426 new cases of cervical cancer in tumor registration area of Yunnan province,ranking fifth in the incidence of female malignant tumors.The crude incidence and ASIRW were 15.83/100,000 and 11.16/100,000,respectively.There were 831 deaths from cervical cancer,ranking sixth deaths of female malignant tumors.The crude mortality and ASMRW were 5.42/100,000 and 3.52/100,000,respectively.ASIRW was higher in rural areas(11.86/100,000)than that in urban areas(9.11/100,000).ASMRW was slightly higher in urban areas(3.63/100,000)than that in rural areas(3.48/100,000).The age-specific incidence of cervical cancer increased rapidly after the age of 20,and reached a peak in the 55-59 age group;The age-specific mortality of cervical cancer increased rapidly after the age of 35,reaching a peak in the 75-79 age group.ASIRW of cervical cancer in Yunnan province from 2012 to 2020 showed a downward trend with annual changes(APC=-7.54%,95% CI:-13.19%-1.53%),and the trend change was statistically significant(P＜0.05).The prediction of the GM(1,1)model showed that the crude incidence and ASIRW of cervical cancer in Yunnan province would continue to decline from 2021 to 2025. Conclusion The incidence and mortality of cervical cancer are relatively low in Yunnan province,but it is still a common malignant tumor in women.The incidence of cervical cancer in Yunnan province is showing a trend of becoming younger,and rural women are the key population for prevention and treatment.

Objective The aim of this study was to analyze the incidence and mortality of esophageal cancer in Yunnan province in 2020,as well as the changing trends from 2012 to 2020,in order to provide the data basis for the prevention and control strategies of esophageal cancer in Yunnan province. Methods The incidence and mortality data of esophageal cancer in tumor registration areas of Yunnan province from 2012 to 2020 were collected and analyzed.The crude incidence,crude mortality,age-standardized incidence rate by Chinese standard population(ASIRC),age-standardized mortality rate by Chinese standard population(ASMRC),age-standardized incidence rate by World standard population(ASIRW)and age-standardized mortality rate by World standard population(ASMRW),0-74 years old cumulative rate and other indicators of esophageal cancer in Yunnan province in 2020 were calculated by gender and age,and the annual incidence and mortality trends of esophageal cancer in Yunnan province from 2012 to 2020 were analyzed by using the Joinpoint regression model. Results In 2020,the crude incidence of esophageal cancer in Yunnan province was 5.84/100,000,including 10.19/100,000 men and 1.28/100,000 women.ASIRC was 3.85/100,000,and ASIRW was 3.88/100,000.The incidence of esophageal cancer was at a low level before the age of 45,rising rapidly after the age of 45,and reached the peak in the 75-79 age group.The crude mortality of esophageal cancer was 5.08/100,000,with a male mortality of 9.02/100,000 and a female mortality of 0.95/100,000.ASMRC was 3.31/100,000,and ASMRW was 3.35/100,000.The mortality of esophageal cancer was at a low level before the age of 50,but rapidly increased after the age of 50,reaching its peak in the 75-79 age group.The incidence and mortality of men in all age groups were higher than those of women.From 2012 to 2020,the crude incidence(APC=8.14%,P＜0.05),ASIRW(APC=7.65%,P＜0.05),crude mortality(APC=8.99%,P＜0.05),and ASMRW(APC=9.20%,P＜0.05)of esophageal cancer all showed an upward trend. Conclusion The incidence and mortality of esophageal cancer in Yunnan province are on the rise.The incidence and mortality of men are higher than those of women.Age is an important factor affecting the occurrence and development of esophageal cancer.Men and the elderly should be the focus of daily intervention.

Objective The aim of this study was to analyze the incidence and mortality of lung cancer in tumor registration areas of Yunnan province in 2020,as well as the changing trends from 2012 to 2020,in order to provide the data support for lung cancer prevention and control. Methods The reported cases of lung cancer from 2012 to 2020 in tumor registration areas of Yunnan province were collected,and SAS 9.4 software was used to calculate the incidence,mortality and other indicators to describe the current situation of lung cancer incidence and mortality.JoinPoint 4.9.0.0 software was used to calculate the annual percentage change(APC)to analyze the trend of lung cancer incidence and mortality. Results In 2020,the crude incidence of lung cancer in Yunnan province was 46.68/100,000(male 58.56/100,000 and female 34.21/100,000),age-standardized incidence rate by Chinese standard population(ASIRC)was 30.83/100,000,age-standardized incidence rate by World standard population(ASIRW)was 30.61/100,000;The crude mortality was 33.88/100,000(male 45.94/100,000 and female 21.21/100,000),age-standardized mortality rate by Chinese standard population(ASMRC)was 21.70/100,000,age-standardized mortality rate by World standard population(ASMRW)was 21.61/100,000.In 2020,the incidence and mortality of lung cancer in Yunnan province showed an upward trend with the increase of age,and was at a low level before the age of 39,and increased rapidly after the age of 40.It reached its peak in the age groups of 75-79 and 80-84,respectively.The crude incidence of lung cancer in urban and rural areas was 47.21/100,000 and 46.52/100,000,respectively;The crude mortality of lung cancer was 32.66/100,000 and 34.27/100,000,respectively.From 2012 to 2020,the crude incidence of lung cancer in Yunnan province increased with the year(APC=2.94%,95% CI=0.29%-5.67%,P＜0.05);The crude incidence of female lung cancer and ASIRW increased with the year(crude incidence rate:APC=6.30%,95% CI=2.52%-10.21%,P＜0.05;ASIRW:APC=5.91%,95% CI=1.21%-10.82%,P＜0.05). Conclusion In 2020,the incidence and mortality of lung cancer in Yunnan province increase significantly after the age of 40.The overall incidence and mortality of lung cancer in men are higher than those in women,and higher in rural areas than that in urban areas.At the same time,the incidence of lung cancer in women is increasing year by year.Therefore,males 40 years old and over above in rural areas should be identified as key populations for lung cancer prevention and control.Simultaneously,women lung cancer also pay attention to the prevention and control.

Objective The aim of this study was to analyze the incidence and mortality of gastric cancer in tumor registration areas of Yunnan province in 2020,as well as the changing trends from 2012 to 2020,and provide suggestion for the prevention and treatment of gastric cancer in Yunnan province. Methods The incidence and death cases of gastric cancer in tumor registration areas of Yunnan province from 2012 to 2020 were collected and complied.After the quality control,the data was included in 89 monitoring points in 2020.Excel 2016 and SPSS 18.0 software were used to calculate the crude incidence,crude mortality,age-standardized incidence rate by World standard population(ASIRW),age-standardized mortality rate by World standard population(ASMRW),cumulative rate and other indicators of gastric cancer in Yunnan province in 2020.Joinpoint 4.8.0.1 software was used to calculate the annual percentage change(APC)and 95% CI of the ASIRW and ASMRW of gastric cancer from 2012 to 2020,and analyze the trend of change. Results In 2020,the crude incidence and ASIRW of gastric cancer in Yunnan province were 11.59/100,000 and 7.60/100,000,respectively.Males(14.90/100,000 and 10.25/100,000)were higher than those in females(8.10/100,000 and 5.04/100,000).In 2020,the crude mortality and ASMRW of gastric cancer in the Yunnan in 2020 were 9.06/100,000 and 5.82/100,000,respectively.Males(11.51/100,000 and 7.89/100,000)were higher than those in females(6.48/100,000 and 3.82/100,000).The crude incidence and mortality of gastric cancer in Yunnan province increased with age.They were at a low level before the age of 45 years old,and then increased rapidly.The 80-84 age group reached the peak(64.12/100,000 and 72.67/100,000),respectively.The APC for ASIRW and ASMRW of gastric cancer in Yunnan province from 2012 to 2020 were-0.35% and 0.22%,respectively,there were no significant difference in the trend of change(P＞0.05). Conclusion ASIRW and ASMRW of gastric cancer of Yunnan province in 2020 are higher for men than women.The trend of ASIRW and ASMRW maintained stable from 2012 to 2020,and the males and middle-aged elderly people over 45 years old in Yunnan province are the key population for gastric cancer prevention and control.

Objective The aim of this study was to analyze the incidence and mortality of liver cancer among residents in cancer registration areas of Yunnan province in 2020,as well as the trend from 2012 to 2020,in order to provide reference for the prevention and control of liver cancer in Yunnan province. Methods The incidence and death data of all liver cancer patients included in the national cancer registration annual report from 2012 to 2020 in tumor registration areas of Yunnan province were collected.The crude incidence and crude mortality of liver cancer in cancer registration areas of Yunnan province in 2020 were analyzed using Excel 2010 and SAS 9.4 statistical software,and the change trend of age-standardized incidence rate by World standard population(ASIRW)and age-standardized mortality rate by World standard population(ASMRW)of liver cancer in cancer registration areas of Yunnan province from 2012 to 2020 was analyzed using Joinpoint 4.8.0.1 software. Results In 2020,the crude incidence of liver cancer in tumor registration areas of Yunnan province was 20.32/100,000(male 29.41/100,000 and female 10.78/100,000),the crude incidence in urban areas was 19.45/100,000,the crude incidence in rural areas was 20.60/100,000.The crude mortality of liver cancer in tumor registration areas of Yunnan province was 20.54/100,000(male 29.60/100,000 and female 11.02/100,000),17.70/100,000 for urban areas,and 21.44/100,000 for rural areas.In 2020,the crude incidence in tumor registration areas of liver cancer in Yunnan province was at a low level before the age of 34,but rapidly increased at the age of 35.The peak rate of the 80-84 age group was 81.37/100,000,and the crude mortality was at a low level before the age of 34.After the age of 35,the mortality rapidly increased,and the peak rate of the 75-79 age group was 92.14/100,000.From 2012 to 2020,the annual change percentage of ASIRW of liver cancer in tumor registration areas of Yunnan province showed an upward trend(APC=1.82%,95% CI:0.07%-3.61%,t=2.45,P＜0.05),and the annual change percentage of ASMRW showed an upward trend(APC=2.88%,95% CI:1.52%-4.26%,t=5.04,P＜0.05). Conclusion In 2020,the crude incidence rate and crude mortality of liver cancer in tumor registration areas of Yunnan Province were higher in men than in women,and higher in rural areas than in urban areas.From 2021-2020,ASIRW and ASMRW of liver cancer are on the rise.We should continue to strengthen the prevention and treatment of liver cancer in Yunnan Province,strengthen the early screening and diagnosis of liver cancer through the combination of medicine and prevention,improve the tumor registration report detection system,strengthen health education,and improve the overall health awareness and cancer prevention knowledge of residents.

Objective The aim of this study was to analyze the incidence and mortality of prostate cancer in cancer registration areas of Yunnan province in 2020,as well as its changing trends from 2012 to 2020,and provide suggestions for the prevention and treatment of prostate cancer in Yunnan province. Methods The data of prostate cancer incidence and mortality in cancer registration areas of Yunnan province from 2012 to 2020 were collected and organized.Excel 2016 and SPSS 18.0 software were used to calculate the crude incidence,crude mortality,age-standardized incidence rate by World standard population(ASIRW),age-standardized mortality rate by Chinese standard population(ASMRC),truncated rate,cumulative rate and other indicators.ASIRW and ASMRC were calculated by using Segi′s World population composition.Joinpoint 4.8.0.1 software was used to calculate the annual percentage change(APC)and 95% CI of ASIRW and ASMRC of prostate cancer from 2012 to 2020,and analyze their annual change trends. Results In 2020,the crude incidence and ASIRW of male prostate cancer in cancer registration areas of Yunnan province were 9.71/100,000 and 6.21/100,000,respectively.ASIRW in urban areas(7.94/100,000)was higher than that in rural areas(5.48/100,000).In 2020,the crude mortality and ASMRC of male prostate cancer in cancer registration areas of Yunnan province were 4.68/100,000 and 2.87/100,000,respectively.ASMRC in urban areas(3.68/100,000)was higher than that in rural areas(2.53/100,000).In 2020,the incidence and mortality of male prostate cancer in Yunnan province increased with age,were at a low level before the age of 45,and began to rise rapidly after the age of 55.From 2012 to 2020,there was no statistically significant change trend in ASIRW and ASMRC of male prostate cancer in Yunnan province(APC were 1.79% and 3.61%,P＞0.05).However,ASIRW and ASMRC of rural males were on the rise(APC were 4.45% and 3.85%,respectively,P＜0.05). Conclusion ASIRW and ASMRC of male prostate cancer in cancer registration areas of Yunnan province in 2020 are higher in urban men than those in rural areas.The change trend of ASIRW and ASMRC from 2012 to 2020 is flat,and rural elderly men should be paid more attention.

Objective The aim of this study was to investigate the mechanism of circ_0008043 regulating glycolysis of hepatocellular carcinoma(HCC)cells. Methods The expression of circ_0008043,miR-198 and SLC2A1 in clinical samples and HCC cell lines was detected by qPCR,and the targeted binding of circ_0008043 to miR-198 and miR-198 to SLC2A1 was verified by dual luciferase reporting assay.HCC cells were transfected with sh-circ_0008043/sh-NC,miR-198 inhibitor/miR-198 inhibitor-NC,miR-198 mimic/mimic NC,or pcDNA3.1-SLC2A1/pcDNA3.1-NC to detected the effects of circ_0008043,miR-198 and SLC2A1 on the glycolysis of HCC cells.The effect of circ_0008043 on tumor growth in HCC was verified by HCC cell xenografts through a nude mouse model. Results circ_0008043 was highly expressed in both HCC tissues and cell lines(P＜0.01).Silencing circ_0008043 could inhibit the glycolysis of HCC cells.The expression of miR-198 was decreased in HCC tissues and cell lines(P＜0.001)and negatively correlated with the expression of circ_0008043(r=-0.550,P＜0.001).The inhibition of glycolysis caused by silencing circ_0008043 was partially restored by inhibiting miR-198 expression.SLC2A1 was highly expressed in HCC tissues and cell lines(P＜0.001),and overexpression of SLC2A1 reversed the inhibitory effect of miR-198 on glycolysis in HCC cells.The nude mouse experiment showed that silencing circ_0008043 could inhibit the growth of HCC cell xenografts(P＜0.001). Conclusion circ_0008043 promotes HCC cell glycolysis and growth through the miR-198/SLC2A1 axis.

Objective The aim of this study was to investigate the regulatory role and mechanism of TRIM24 in endocrine therapy resistance of breast cancer. Methods The relationship between TRIM24 expression and prognosis in breast cancer patients receiving endocrine therapy was analyzed by the Kaplan-Meier Plotter database.After treatment of breast cancer MCF7 cells or T47D cells with tamoxifen(TAM),the expression of TRIM24 was detected by qRT-PCR and Western blot.After knocking out TRIM24 in TAM sensitive MCF7/S0.5 cells and resistant cells MCF7/TAMR-1 cells,cell proliferation was measured by CCK 8 assay.After knocking out the estrogen receptor(ER)or treating with the selective progesterone receptor(PR)antagonist UPA(Ulipristal acetate)in MCF7 cells,the expression of TRIM24 was measured by qRT-PCR and Western blot.After PR was overexpressed in MCF7 cells,the expression of TRIM24 was detected by Western blot.The expression of human epidermal growth factor receptor 2(HER2)was detected by qRT PCR and Western blot after the overexpression of TRIM24. Results Among breast cancer patients receiving endocrine therapy,patients with high expression of TRIM24 had a shorter recurrence free survival(RFS)(P=0.027).TAM treatment could induce an increase of TRIM24 expression(P＜0.001);Knocking out TRIM24 significantly inhibited the proliferation of drug-resistant MCF7/TAMR-1 cells(P＜0.001),but had no effect on sensitive MCF7/S0.5 cells;After knocking out ER or treatment of PR antagonist,the expression of TRIM24 could be upregulated in MCF7 cells(P＜0.01),while overexpression of PR could down-regulate the expression of TRIM24.TRIM24 could activate the expression of HER2(P＜0.05). Conclusion PR negatively regulation of TRIM24 plays an important role in endocrine therapy resistance of breast cancer.

Objective The aim of this study was to investigate the effect of B cell translocation gene 3(BTg-3)on proliferation,invasion,migration and protein kinase B/glycogen synthase kinase-3β/β-catenin(Akt/GSK-3β/β-catenin)signaling pathway of liver cancer cells. Methods Western blot was used to measure the expression of BTg-3 protein in liver cancer BEL-7402 cells,SMMC-7721 cells,HepG2 cells and normal liver cancer LO2 cells.HepG2 cells were divided into the blank control group(N group),empty vector group(V group),BTg-3 overexpression group(BTg-3 group)and BTg-3 overexpression + LICL group(BTg-3+LICL group).HepG2 cells in the N group were not transfected and HepG2 cells of the V group were transfected with empty vector pcDNA3.1.HepG2 cells in the BTg-3 group were transfected overexpressing BTg-3 vector pcDNA3.1-BTg-3,while HepG2 cells in the BTg-3 overexpression + LiCl group were transfected with the BTg-3 vector pcDNA3.1-BTg-3 and treated with 10 nmol/l GSK-3β inhibitor-lithium chloride(LiCl).MTT assay was used to determine the proliferative ability of HepG2 cells in each group.The cell colony formation assay was used to determine the survival ability of HepG2 cells in each group.Transwell assay was used to determine the invasive and migratory ability of HepG2 cells in each group.Western blot was used to determine the expression of Akt,phosphorylated Akt(p-Akt),p-GSK-3β,β-catenin,Cyclin D1,N-cadherin and epithelial cadherin(E-cadherin)in HepG2 cells. Results The expression of BTg-3 protein in human liver cancer BEL-7402 cells,SMMC-7721 cells and HepG2 cells were lower than that in normal liver LO2 cells(P＜0.001).Compared with the N group and V group,the A values and clone formation rates were decreased in the BTg-3 group and BTg-3+LICL group(P＜0.05),as well as a decrease in the number of invasive cells and migratory cells(P＜0.05).The expression of p-Akt,p-GSK-3β,β-catenin,Cyclin D1 and N-cadherin proteins decreased(P＜0.05),and the expression of BTg-3 and E-cadherin proteins increased(P＜0.05)in the BTg-3 group and BTg-3+LICL group.Compared with the BTg-3 group,the A values and clone formation rate in the BTg-3+LICL group increased(P＜0.05),as well as an increase in the number of invasive cells and migratory cells(P＜0.05).The expression of p-Akt,p-GSK-3β,β-catenin,Cyclin D1 and N-cadherin proteins increased(P＜0.05),while the expression of BTg-3 and E-cadherin proteins in HepG2 cells decreased in the BTg-3+LICL group(P＜0.05).There were no significant differences in the indexes of HepG2 cells between the N group and V group(P＞0.05). Conclusion BTg-3 is lowly expressed in liver cancer cells,and overexpression BTg-3 may inhibit proliferation,invasion and migration of liver cancer cells through the Akt/GSK-3β/β-catenin signaling pathway.

Cancer patients are a high risk group for malnutrition.The decreased intake,impaired absorption,abnormal utilization,increased consumption and increased demand are the main causes of malnutrition in oncology patients.Malnutrition can lead to adverse outcomes such as reduced tolerance to anti-cancer therapy,decreased quality of life for patients,shortened survival time,and increased medical costs.Therefore,standardized nutritional therapy for oncology patients should become an important part of comprehensive cancer treatment and be carried out through the entire life cycle of cancer patients.This article describes the indications,timing and duration of nutritional therapy,treatment goals and the five-step therapeutic approaches,the energy and protein requirements of oncology patients,the characteristics of tumor-specific nutritional formulas,and evaluation of the effectiveness of nutritional therapy,in order to provide guidance for clinical nutritional therapy for cancer patients.

Lung cancer is one of the most common cancers.Although there has been a significant improvement in our understanding the risk,development,immune control,and treatment options of lung cancer,the limited understanding of its pathogenesis has resulted in insufficient targeted treatment strategies.In recent years,RNA methylation has become a research hot topic in the field of epigenetics,and proteins regulating RNA methylation have become important targets for cancer treatment.At present,some studies have reported the relationship between RNA methylation and biological processes such as oncogene expression,glycolysis,and immune response in lung cancer,but there is still no in-depth research and analysis.This article will start with the relationship between RNA methylation and lung cancer,explore the association between RNA methylation and the pathogenesis of lung cancer based on existing research,and discuss its future development direction.